Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (e.g., infliximab, adalimumab [AbbVie / Eisai’s Humira, biosimilars]), together with non-TNF biologics (i.e., Takeda’s Entyvio and Johnson & Johnson Innovative Medicine’s Stelara), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs’ efficacy limitations and safety risks. The recent approvals and impending entry of several new therapies that offer more-convenient formulations and/or novel mechanisms of action (e.g., AbbVie’s Skyrizi and Rinvoq, Eli Lilly’s mirikizumab, Johnson & Johnson Innovative Medicine’s Tremfya) will further improve treatment and intensify market competition. Together with these trends, the continuing generic erosion of conventional agents and the availability of biosimilar TNF-α inhibitors will constrain CD therapy sales.


  • What are KOLs’ opinions of current targeted therapies (e.g., infliximab, adalimumab, Stelara, Entyvio)? How have biosimilars influenced treatment practices? What factors drive treatment decisions?
  • What do KOLs think about recently approved and emerging therapies (e.g., Skyrizi, Rinvoq, mirikizumab, Tremfya)? What impact will the stem cell therapy Alofisel (TiGenix / Takeda) and oral therapies have on the CD treatment algorithm?
  • Which emerging agents will be most successful in targeting TNF-refractory patients and experiencing uptake in the CD market?
  • How will the market evolve over the next 10 years?


Geographies: United States, EU5, Japan.

Primary research: 25 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of CD by country, segmented by disease activity.

Forecast: 10-year, annualized, drug-level sales and patient share of key CD therapies through 2032, segmented by brands/generics.

Emerging therapies: Phase 3/preregistered: ~4 drugs; coverage of select Phase 1 and Phase 2 products.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports